Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

XC8 Safety, Tolerability and Pharmacokinetics in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03441815
Recruitment Status : Completed
First Posted : February 22, 2018
Last Update Posted : February 22, 2018
Sponsor:
Information provided by (Responsible Party):
PHARMENTERPRISES LLC

Brief Summary:

A double-blind, randomized, placebo-controlled, Phase I clinical study of the safety and tolerability of increasing doses of XC8 after single and repeated oral administration in healthy volunteers. The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.

The primary objective of the study was to evaluate the safety and tolerability profile for XC8 after single and multiple administration based on the frequency and severity of adverse events and changes in vital signs, laboratory results, electrocardiography and results of the physical examination.

The secondary objective of the study was to assess pharmacokinetics of XC8.


Condition or disease Intervention/treatment Phase
Asthma Drug: XC8 Drug: Placebo Phase 1

Detailed Description:

One Russian center was approved for participation in this study. One center was initiated. Healthy volunteers were enrolled in 1 center. The study consisted of 4 periods: screening, single administration, multiple administration and follow-up.

All eligible subjects were randomized into the study in appropriate cohort groups sequentially.

Cohort 1 - XC8 or Placebo 2 mg once and then daily 14 days after a 6-day break; Cohort 2 - XC8 or Placebo 10 mg once and then daily during 14 days after a 6-day break; Cohort 3 - XC8 or Placebo 50 mg once and then daily during 14 days after a 6-day break; Cohort 4 - XC8 or Placebo 200 mg once and then daily during 14 days after a 6-day break.

The decision regarding increasing of the study drug dose for a subsequent cohort was made by the Data Safety Monitoring Committee on the basis of preliminary safety results assessment.

A total of 20 volunteers received XC8 (2 mg, 10 mg, 50 mg or 200 mg) and a total of 8 volunteers received the placebo during the study participation. The follow-up period lasted for 4 weeks.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: The dose cohorts were included into the study subsequently based on preliminary safety results evaluation performed by the Data Safety Monitoring Committee. 4 doses of XC8/placebo (2 mg, 10 mg, 50 mg and 200 mg) were used in the study.The duration of exposure to the study drug was 15 days in each cohort: Day 1, once, at the step of single administration, and then in 6 days, daily, 1 time a day for 14 days at the step of multiple administration.
Masking: Double (Participant, Investigator)
Masking Description: Blinding was carried out by using Placebo equivalent to XC8 tablets without active substance and the corresponding labeling of the study drug.
Primary Purpose: Treatment
Official Title: A Double-blind, Randomized, Placebo-controlled Study of the Safety and Tolerability of Increasing Doses of XC8 After Single and Repeated Oral Administration in Healthy Volunteers
Actual Study Start Date : February 14, 2015
Actual Primary Completion Date : July 7, 2015
Actual Study Completion Date : July 7, 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: XC8 2 mg
Cohort 1: 6 subjects were randomized in a 2:1 ratio to be treated either with 2 mg XC8 (4 subjects) or placebo (2 subjects, see placebo arm).
Drug: XC8
Other Name: Histamine glutarimide

Experimental: XC8 10 mg
Cohort 2: 6 subjects were randomized in a 2:1 ratio to be treated either with 10 mg XC8 (4 subjects) or placebo (2 subjects, see placebo arm).
Drug: XC8
Other Name: Histamine glutarimide

Experimental: XC8 50 mg
Cohort 3: 6 subjects were randomized in a 2:1 ratio to be treated either with 50 mg XC8 (4 subjects) or placebo (2 subjects, see placebo arm).
Drug: XC8
Other Name: Histamine glutarimide

Experimental: XC8 200 mg
Cohort 4: 10 subjects were randomized in a 4:1 ratio to be treated either with 200 mg XC8 (8 subjects) or placebo (2 subjects, see placebo arm).
Drug: XC8
Other Name: Histamine glutarimide

Placebo Comparator: Placebo
Placebo comparator arm consists of 8 subjects (2 subjects in each cohort).
Drug: Placebo



Primary Outcome Measures :
  1. Number of Adverse events per treatment arm [ Time Frame: Change from pre-dose to Day 50 ]
    Adverse events will be summarized descriptively by treatment arm. Verbatim terms will be mapped to preferred terms and organ systems using the current Medical Dictionary for Regulatory Activities version. For each preferred term, frequency counts and percentages will be calculated by cohort.The nature, severity, seriousness, and relationship to study medication will be summarized for all study subjects

  2. Physical examination [ Time Frame: Day 1 till Day 36 ]
    Physical examination results will be listed for following: general appearance, skin, head, eyes, ears, nose, throat, neck (including thyroid), lymph nodes, chest, heart, abdomen (including liver examination), extremities, and nervous system.

  3. 12-lead ECG [ Time Frame: Change from pre-dose till Day 36 ]
    12-lead ECG results will be analyzed descriptively


Secondary Outcome Measures :
  1. Pharmacokinetics of XC8 by assessing AUC0-inf [ Time Frame: Day 1 and 21 (Pre dose, and 20 min, 40 min, 1, 2, 4, 6 and 10 hours post dose), Day 2 and Day 22 (24 hours ±10 minutes post dose), Day 3 (48 hours ±10 minutes post dose), Day 4 (72 hours ±10 minutes post dose), Day 8 to 12 and 15 (Pre dose) ]
    Area under the curve "concentration of the drug-time" from the time of administration of the drug till infinity

  2. Pharmacokinetics of XC8 by assessing Cmax [ Time Frame: Day 1 and 21 (Pre dose, and 20 min, 40 min, 1, 2, 4, 6 and 10 hours post dose), Day 2 and Day 22 (24 hours ±10 minutes post dose), Day 3 (48 hours ±10 minutes post dose), Day 4 (72 hours ±10 minutes post dose), Day 8 to 12 and 15 (Pre dose) ]
    Maximum plasma concentration

  3. Pharmacokinetics of XC8 by assessing AUC0-t [ Time Frame: Day 1 and 21 (Pre dose, and 20 min, 40 min, 1, 2, 4, 6 and 10 hours post dose), Day 2 and Day 22 (24 hours ±10 minutes post dose), Day 3 (48 hours ±10 minutes post dose), Day 4 (72 hours ±10 minutes post dose), Day 8 to 12 and 15 (Pre dose) ]
    Area under the curve "concentration of the drug-time" from the time of administration of the drug till the time (t) the last blood sampling

  4. Pharmacokinetics of XC8 by assessing Tmax [ Time Frame: Day 1 and 21 (Pre dose, and 20 min, 40 min, 1, 2, 4, 6 and 10 hours post dose), Day 2 and Day 22 (24 hours ±10 minutes post dose), Day 3 (48 hours ±10 minutes post dose), Day 4 (72 hours ±10 minutes post dose), Day 8 to 12 and 15 (Pre dose) ]
    Time to maximum drug concentration in the blood plasma administration

  5. Pharmacokinetics of XC8 by assessing T1/2 [ Time Frame: Day 1 and 21 (Pre dose, and 20 min, 40 min, 1, 2, 4, 6 and 10 hours post dose), Day 2 and Day 22 (24 hours ±10 minutes post dose), Day 3 (48 hours ±10 minutes post dose), Day 4 (72 hours ±10 minutes post dose), Day 8 to 12 and 15 (Pre dose) ]
    Terminal elimination half-life

  6. Pharmacokinetics of XC8 by assessing kel [ Time Frame: Day 1 and 21 (Pre dose, and 20 min, 40 min, 1, 2, 4, 6 and 10 hours post dose), Day 2 and Day 22 (24 hours ±10 minutes post dose), Day 3 (48 hours ±10 minutes post dose), Day 4 (72 hours ±10 minutes post dose), Day 8 to 12 and 15 (Pre dose) ]
    Elimination rate constant

  7. Pharmacokinetics of XC8 by assessing Cav [ Time Frame: Day 8 to 12 and 15 (Pre dose); Day 21 (Pre dose, and 20 min, 40 min, 1, 2, 4, 6 and 10 hours post dose), Day 22 (24 hours ±10 minutes post dose ]
    Average concentration over one dosing interval



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Non-smoking men aged 18 to 50 years (inclusive);
  2. Verified diagnosis "healthy" according to standard clinical, laboratory and instrumental methods of examination;
  3. Body mass index of 19 to 30 kg/m2 (inclusive);
  4. Consent to use reliable methods of contraception during the study and 3 months after its completion (condoms with spermicide);
  5. Signed patient information sheet and informed consent form for participation in the study.

Exclusion Criteria:

  1. Hepatic disorder or renal disease; any other disease that, in the opinion investigator, may affect the results of the study, or may lead to the health aggravation during the study;
  2. Laboratory abnormalities at screening;
  3. Course intake of medicinal products (including herbs and biologically active additives) for preventive or curative purposes within 1 month prior to screening;
  4. Antibodies to HIV and hepatitis C virus, the presence of the hepatitis B surface antigen, a positive syphilis test;
  5. The presence of a sleep disorder (for example, night work, sleep disturbances, insomnia, recent return from another time zone, etc.);
  6. Signs of alcohol or drug abuse; taking alcohol or drugs during 4 days before screening;
  7. History of allergies (including medicines and food products);
  8. Symptomatic rhinitis in anamnesis during 2 years prior to screening (allergic rhinitis, non-allergic rhinitis or pollinosis);
  9. Blood donation / plasma, surgical intervention (in a hospital environment) during 12 weeks before screening;
  10. Participation in other clinical trials or taking the study drug during 3 months before screening;
  11. Impossibility to understand or follow protocol instructions;
  12. Smoking 3 months before screening;
  13. Lactase deficiency, lactose intolerance, glucose-galactose malabsorption;
  14. Acute infectious diseases less than 4 weeks before the start of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03441815


Locations
Layout table for location information
Russian Federation
SBEI HPE The First Moscow State Medical University n.a. Sechenov of Ministry of Health of Russian Federation, University Hospital #2, Department of Development of New Medicines
Moscow, Russian Federation, 119435
Sponsors and Collaborators
PHARMENTERPRISES LLC

Layout table for additonal information
Responsible Party: PHARMENTERPRISES LLC
ClinicalTrials.gov Identifier: NCT03441815     History of Changes
Other Study ID Numbers: PULM-XC8-01
First Posted: February 22, 2018    Key Record Dates
Last Update Posted: February 22, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by PHARMENTERPRISES LLC:
Healthy volunteers
Phase I
Histamine glutarimide
PHARMENTERPRISES
Additional relevant MeSH terms:
Layout table for MeSH terms
Histamine
Histamine phosphate
Glutarimide
Histamine Agonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Protein Synthesis Inhibitors
Enzyme Inhibitors